3. Duplicative Therapy

There are no FDA indications for duplicate therapy with multiple combination drug products (e.g. ledipasvir/ sofosbuvir (Harvoni®) with glecaprevir/pibrentasvir (Mavyret™))2-11.

Ribavirin combination therapy is indicated in patients with more advanced liver disease and HCV genotypes that are found to be more resistant (e.g. genotype 3)1,11.

For recommended combination therapies see Duration of Therapy tables above (Tables 1-3).